ARTICLE | Deals
In Arctos deal, Novartis adds preclinical sight-restoring therapy
September 21, 2021 5:19 AM UTC
Novartis’ acquisition of Arctos gives the pharma a preclinical, vector-delivered therapy that could restore sight in people whose loss of vision is attributable to a wide spectrum of causes, while also generating a return for the Swiss biotech’s early investors including ND Capital.
ND Capital’s Dani Bach told BioCentury that Novartis AG (NYSE:NVS; SIX:NOVN) edged out two other interested suitors to acquire Arctos Medical AG...